Lynza 150mg Tablet

About Lynza 150mg Tablet

Lynza 150mg Tablet contains Olaparib, a targeted anticancer medication belonging to the PARP (Poly ADP-ribose Polymerase) inhibitor class. It is used in the treatment of certain cancers, including pancreatic cancer and prostate cancer, and may be prescribed alone or in combination with other anticancer therapies depending on the patient's condition. Olaparib works by blocking PARP enzymes that help cancer cells repair damaged DNA, leading to cancer cell death and slowing disease progression. Patients should not take Lynza 150mg Tablet if they are allergic to Olaparib or any of its ingredients. Before starting treatment, it is important to inform your healthcare provider about any history of lung, liver, kidney, or heart disease, as these conditions may require closer monitoring. Regular blood tests are recommended before and throughout treatment, as Olaparib may reduce red blood cells, white blood cells, and platelet counts, increasing the risk of anemia, infections, and bleeding. Patients should seek immediate medical attention if they experience symptoms such as shortness of breath, chest pain, rapid heartbeat, fever, cough, or wheezing. This medication is not recommended during pregnancy because it may harm an unborn baby or cause miscarriage. Women of childbearing potential should undergo a pregnancy test before treatment and use effective contraception during therapy and for at least six months after the last dose. Breastfeeding is not recommended during treatment, as it is unknown whether Olaparib passes into breast milk. Male patients should avoid donating sperm during treatment and for at least three months after completing therapy. To ensure safe and effective treatment, patients should inform their doctor about all prescription medications, over-the-counter drugs, vitamins, and dietary supplements they are taking before starting Lynza 150mg Tablet.